Global Diabetes Mellitus Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Diabetes Mellitus Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia.High blood sugar is caused by defective secretion of insulin or impaired biological function, or both.Long-term hyperglycemia leads to chronic damage and dysfunction of various tissues, especially eyes, kidneys, heart, blood vessels and nerves.
Diabetes Mellitus Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Diabetes Mellitus Drugs market is projected to reach US$ 80020 million in 2034, increasing from US$ 53520 million in 2022, with the CAGR of 6.0% during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Diabetes Mellitus Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Diabetes Mellitus Drugs key companies include Novo Nordisk, Merck & Co, Boehringer Ingelheim, AstraZeneca, Eli Lilly and Company, Johnson & Johnson, Takeda, Sanofi and Gan & Lee Pharmaceuticals, etc. Novo Nordisk, Merck & Co, Boehringer Ingelheim are top 3 players and held % share in total in 2022.
Diabetes Mellitus Drugs can be divided into Oral Medicine and Injection Medicine, etc. Oral Medicine is the mainstream product in the market, accounting for % share globally in 2022.
Diabetes Mellitus Drugs is widely used in various fields, such as Hospital, Clinic and Others,, etc. Hospital provides greatest supports to the Diabetes Mellitus Drugs industry development. In 2022, global % share of Diabetes Mellitus Drugs went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diabetes Mellitus Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Novo Nordisk
Merck & Co
Boehringer Ingelheim
AstraZeneca
Eli Lilly and Company
Johnson & Johnson
Takeda
Sanofi
Gan & Lee Pharmaceuticals
Bayer
Tonghua Dongbao Pharmaceutical Co
Huadong Medicine
Segment by Type
Oral Medicine
Injection Medicine
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Diabetes Mellitus Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Diabetes Mellitus Drugs introduction, etc. Diabetes Mellitus Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Diabetes Mellitus Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Diabetes Mellitus Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Diabetes Mellitus Drugs market is projected to reach US$ 80020 million in 2034, increasing from US$ 53520 million in 2022, with the CAGR of 6.0% during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Diabetes Mellitus Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Diabetes Mellitus Drugs key companies include Novo Nordisk, Merck & Co, Boehringer Ingelheim, AstraZeneca, Eli Lilly and Company, Johnson & Johnson, Takeda, Sanofi and Gan & Lee Pharmaceuticals, etc. Novo Nordisk, Merck & Co, Boehringer Ingelheim are top 3 players and held % share in total in 2022.
Diabetes Mellitus Drugs can be divided into Oral Medicine and Injection Medicine, etc. Oral Medicine is the mainstream product in the market, accounting for % share globally in 2022.
Diabetes Mellitus Drugs is widely used in various fields, such as Hospital, Clinic and Others,, etc. Hospital provides greatest supports to the Diabetes Mellitus Drugs industry development. In 2022, global % share of Diabetes Mellitus Drugs went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Diabetes Mellitus Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Novo Nordisk
Merck & Co
Boehringer Ingelheim
AstraZeneca
Eli Lilly and Company
Johnson & Johnson
Takeda
Sanofi
Gan & Lee Pharmaceuticals
Bayer
Tonghua Dongbao Pharmaceutical Co
Huadong Medicine
Segment by Type
Oral Medicine
Injection Medicine
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Diabetes Mellitus Drugs market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Diabetes Mellitus Drugs introduction, etc. Diabetes Mellitus Drugs Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Diabetes Mellitus Drugs market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices